The effects of combined angiotensin converting enzyme inhibition and beta-adrenoceptor blockade on plasma renin activity in anaesthetized dogs
- PMID: 1356560
- PMCID: PMC1907514
- DOI: 10.1111/j.1476-5381.1992.tb14338.x
The effects of combined angiotensin converting enzyme inhibition and beta-adrenoceptor blockade on plasma renin activity in anaesthetized dogs
Abstract
1. The effects of beta-adrenoceptor blockade on the changes in plasma renin activity (PRA) following angiotensin enzyme (ACE) inhibition were investigated in pentobarbitone-chloralose anaesthetized dogs. 2. ACE-inhibition, with enalapril (2 mg kg-1), caused a significant reduction in systemic arterial blood pressure (BP) with little or no effect on cardiac function, and a significant elevation of plasma renin activity (PRA). By contrast beta-adrenoceptor blockade with atenolol (1 mg kg-1), caused a similar reduction in BP but in addition, significantly reduced cardiac function and PRA. 3. A combination of enalapril with atenolol, caused a significant reduction in BP, cardiac function and PRA, hence there was no elevation of PRA, as was seen following ACE-inhibition with enalapril alone. 4. The observations with beta-adrenoceptor blockade alone, show that there is an important homeostatic role for the renal sympathetic innervation, mediated by beta-adrenoceptors, in controlling basal renin levels. Furthermore, the renal sympathetic innervation appears to be an important contributor to the renin release caused by an ACE-inhibitor as the additional presence of a beta-adrenoceptor blocking agent will prevent this release. 5. BW B385C (2 mg kg-1), which combines both ACE-inhibition and beta-adrenoceptor blocking properties, also produced reductions in BP and cardiac function similar to those seen with the enalapril/atenolol combination. In addition, for an equivalent degree of ACE-inhibition by BW 385C, to that seen with enalapril alone, the elevation of PRA was attenuated. 6. A combination of ACE-inhibition and beta-adrenoceptor blocking activity in a single entity, such as BW B385C, therefore also produces a reduced renin release when compared with an ACE-inhibitor, such as enalapril. This provides further confirmation of the importance of the renal sympathetic innervation in the renin response to ACE-inhibition, and supports the concept of combining ACEinhibition with beta-adrenoceptor blockade.
Similar articles
-
Cardiac and renovascular effects in the anaesthetized dog of BW A575C: a novel angiotensin converting enzyme inhibitor with beta-adrenoceptor blocking properties.Br J Pharmacol. 1988 Jan;93(1):165-75. doi: 10.1111/j.1476-5381.1988.tb11418.x. Br J Pharmacol. 1988. PMID: 2894874 Free PMC article.
-
Adjunctive sympathoplegic therapy to ACE inhibition in Blacks with congestive heart failure: a comparison of alpha-1 with beta-1 blockade on exercise tolerance and cardiac sympathovagal reflex activity.Ethn Dis. 2003 Winter;13(1):71-9. Ethn Dis. 2003. PMID: 12723015 Clinical Trial.
-
Differing early blood pressure and renin-angiotensin system responses to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure.J Cardiovasc Pharmacol. 1996 May;27(5):657-66. doi: 10.1097/00005344-199605000-00007. J Cardiovasc Pharmacol. 1996. PMID: 8859935 Clinical Trial.
-
Comparison of beta-blockade and ACE inhibitors in the treatment of hypertension.J Cardiovasc Pharmacol. 1990;16 Suppl 5:S81-5. J Cardiovasc Pharmacol. 1990. PMID: 11527141 Review.
-
Beta blockers or angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker: what should be first?Cardiol Clin. 2007 Nov;25(4):581-94; vii. doi: 10.1016/j.ccl.2007.09.004. Cardiol Clin. 2007. PMID: 18063162 Review.
Cited by
-
Altered responses to vasopressors of a patient medicated with carvedilol, pilsicainide and enalapril.J Anesth. 2014 Aug;28(4):625-7. doi: 10.1007/s00540-013-1762-x. Epub 2013 Dec 24. J Anesth. 2014. PMID: 24366327
-
Low-dose combination therapy with metoprolol and captopril for congestive heart failure in mice.Cardiovasc Drugs Ther. 1993 Nov;7(5):795-800. doi: 10.1007/BF00878933. Cardiovasc Drugs Ther. 1993. PMID: 8110623
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous